Back to top

Botanix: Sofdra Launch Momentum and Revenue Recovery Support Unchanged $1 Price Target and Buy Rating

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Botanix Pharmaceuticals Limited, with a price target o...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: